About Intomics
Intomics is a company based in Lyngby (Denmark) founded in 2008 was acquired by ZS in May 2022. Intomics has raised $372.03 thousand across 3 funding rounds from investors including ZS, European Union and SEED Capital. The company has 27 employees as of December 31, 2021. Intomics operates in a competitive market with competitors including NantHealth, BioAge Labs, Perthera, Ontoforce and Genedata, among others.
- Headquarter Lyngby, Denmark
- Employees 27 as on 31 Dec, 2021
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Intomics A / S
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Intomics
Intomics has successfully raised a total of $372.03K across 3 strategic funding rounds. The most recent funding activity was a Seed round of $40.3 thousand completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Intomics
Intomics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include ZS, European Union and SEED Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm backing Nordic tech startups from seed to Series A with investments in Consumer, Deep Tech, and related sectors.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Strategic and management consulting services are provided worldwide.
|
Locked | Locked | Locked |
Investor details for Intomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Intomics
Investment portfolio details for Intomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Intomics
Detailed financials for Intomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Intomics Comparisons
Peer comparison for Intomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Intomics
Intomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NantHealth, BioAge Labs, Perthera, Ontoforce and Genedata, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Bioinformatics platforms are provided for cancer treatment identification.
|
|
| Locked | Locked | Locked |
Bioinformatics platform is provided for biomarkers and drug discovery.
|
|
| Locked | Locked | Locked |
Molecular cancer profiling is conducted via genomics and proteomics.
|
|
| Locked | Locked | Locked |
Semantic search platform is provided for pharmaceutical and biotech research.
|
|
| Locked | Locked | Locked |
Software solutions are developed for drug discovery and life sciences.
|
|
| Locked | Locked | Locked |
AI-powered real-world data platform is provided for clinical development.
|
Detailed competitors of Intomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Intomics
Complete news archive for Intomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Intomics
Intomics was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Intomics is headquartered in Lyngby, Denmark. It is registered at Lyngby, Region Hovedstaden, Denmark.
Intomics is a funded company, having raised a total of $372.03K across 3 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Intomics is 27.
Intomics was founded in 2008 and is based in Lyngby, Denmark. Operations focus on the bioinformatics sector, where biomedical big data is analyzed and integrated through the InBio Platform, which employs proprietary algorithms for mining heterogeneous data sources. Key services encompass drug target identification, biomarker discovery, translational research support, drug repositioning for new disease applications, and personalized medicine solutions.
Intomics's top competitors include NantHealth, BioAge Labs and Genedata.
Intomics has 3 investors. Key investors include ZS, European Union, and SEED Capital.
The valuation of Intomics is $1.38M as of Dec 2021.